SCHEMBL3570137

SCHEMBL3570137

C=CCOC(=O)Cc1c[nH]c2cccc(Br)c12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.45
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
ALDH1A1 P00352 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
LMNA P02545 1/20 0.45
PKM P14618 2/20 0.43
GAA P10253 2/20 0.43
KDM4E B2RXH2 1/20 0.43
POLB P06746 1/20 0.43
THRB P10828 1/20 0.43
DNMT1 P26358 1/20 0.43
RECQL P46063 1/20 0.43
CASP6 P55212 1/20 0.43
MCL1 Q07820 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
CYP2A6 P11509 1/20 0.43
NPSR1 Q6W5P4 2/20 0.42
CYP3A4 P08684 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3560986 0.80 ALDH1A1 (0.48) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL2188020 0.79 MAPT (0.72) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL6404376 0.77 CYP3A4 (0.42) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL3562093 0.77 ALDH1A1 (0.69) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL3266396 0.77 CYP3A4 (0.49) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL460462 0.72 HTR2A (0.42) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL28030373 0.71 CYP3A4 (0.56) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL2463168 0.71 NPSR1 (0.60) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL9936651 0.70 PKM (0.63) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL25381397 0.70 CYP2A6 (0.50) MAPTMEN1KMT2AALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1852420-B1 Indole compounds for treating respiratory disorders ONO PHARMACEUTICAL CO (JP) 2012-10-17 EP disclosed
US-7728023-B2 Indole compound and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2010-06-01 US disclosed
US-20080188532-A1 Indole Compound and Use Thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2008-08-07 US disclosed
CN-101128424-A Indole compound and use thereof ONO PHARMACEUTICAL CO (JP) 2008-02-20 CN disclosed
EP-1852420-A1 INDOLE COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2007-11-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188532-A1 Indole Compound and Use Thereof CYSLTR1, LTC4S, IDO1 MAPT 2921/4885MEN1 4327/4885KMT2A 2961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.